Search research articles
Contact Us
Filters
Showing results (1-10 of 268) with videos related to
Page
of 27
Sort By:
European Urology
|
August 25, 2016
Re: <sup>225</sup>Ac-PSMA-617 for PSMA-Targeting Alpha-radiation Therapy of Patients with Metastatic Castration-resistant Prostate Cancer
Boris Hadaschik
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
September 3, 2021
[Radiation therapy in high-risk and very high-risk localized or locally advanced prostate cancer : Prostate-only versus prostate plus whole-pelvic?]
Martin Stuschke, Boris Hadaschik
European Urology
|
May 7, 2020
Re: Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multi-centre Study
Boris Hadaschik, Ken Herrmann
European Urology
|
July 27, 2021
Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Boris Hadaschik, Ken Herrmann
Der Urologe. Ausg. A
|
April 12, 2022
[Imaging update for urologists : Modern diagnostics in hospitals and medical practices]
Boris Hadaschik, Christian Stief
European Urology
|
July 31, 2025
Re: Salvage Metastasis-directed Therapy Versus Elective Nodal Radiotherapy for Oligorecurrent Nodal Prostate Cancer Metastases (PEACE V-STORM): A Phase 2, Open-label, Randomised Controlled Trial
Christian Thomas, Boris Hadaschik
European Urology
|
December 25, 2018
Re: Preliminary Results for Avelumab Plus Axitinib as First-Line Therapy in Patients with Advanced Clear-cell Renal-cell Carcinoma (JAVELIN Renal 100): An Open-label, Dose-finding and Dose-expansion, Phase 1b Trial
Viktor Grünwald, Boris Hadaschik
European Urology
|
May 28, 2019
Re: Assessment of <sup>68</sup>Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial
Boris Hadaschik, Piet Ost
Urologie (Heidelberg, Germany)
|
December 6, 2023
[Metastatic castration-resistant prostate cancer: practical guidance for personalized decision-making]
Boris Hadaschik, Axel Merseburger
European Urology
|
May 16, 2021
Re: Nivolumab plus Cabozantinib Versus Sunitinib for Advanced Renal-cell Carcinoma
Viktor Grünwald, Boris Hadaschik
Page
of 27
Search research articles
Search
Showing results (1-10 of 268) with videos related to
Sort By:
Page
of 27
European Urology
|
August 25, 2016
Re: <sup>225</sup>Ac-PSMA-617 for PSMA-Targeting Alpha-radiation Therapy of Patients with Metastatic Castration-resistant Prostate Cancer
Boris Hadaschik
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]
|
September 3, 2021
[Radiation therapy in high-risk and very high-risk localized or locally advanced prostate cancer : Prostate-only versus prostate plus whole-pelvic?]
Martin Stuschke, Boris Hadaschik
European Urology
|
May 7, 2020
Re: Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multi-centre Study
Boris Hadaschik, Ken Herrmann
European Urology
|
July 27, 2021
Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Boris Hadaschik, Ken Herrmann
Der Urologe. Ausg. A
|
April 12, 2022
[Imaging update for urologists : Modern diagnostics in hospitals and medical practices]
Boris Hadaschik, Christian Stief
European Urology
|
July 31, 2025
Re: Salvage Metastasis-directed Therapy Versus Elective Nodal Radiotherapy for Oligorecurrent Nodal Prostate Cancer Metastases (PEACE V-STORM): A Phase 2, Open-label, Randomised Controlled Trial
Christian Thomas, Boris Hadaschik
European Urology
|
December 25, 2018
Re: Preliminary Results for Avelumab Plus Axitinib as First-Line Therapy in Patients with Advanced Clear-cell Renal-cell Carcinoma (JAVELIN Renal 100): An Open-label, Dose-finding and Dose-expansion, Phase 1b Trial
Viktor Grünwald, Boris Hadaschik
European Urology
|
May 28, 2019
Re: Assessment of <sup>68</sup>Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial
Boris Hadaschik, Piet Ost
Urologie (Heidelberg, Germany)
|
December 6, 2023
[Metastatic castration-resistant prostate cancer: practical guidance for personalized decision-making]
Boris Hadaschik, Axel Merseburger
European Urology
|
May 16, 2021
Re: Nivolumab plus Cabozantinib Versus Sunitinib for Advanced Renal-cell Carcinoma
Viktor Grünwald, Boris Hadaschik
Page
of 27